Walleye Trading LLC Invests $2.70 Million in Bruker Corporation $BRKR

Walleye Trading LLC purchased a new position in Bruker Corporation (NASDAQ:BRKR) during the 2nd quarter, Holdings Channel.com reports. The firm purchased 44,895 shares of the medical research company’s stock, valued at approximately $2,702,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BRKR. Royal Bank of Canada boosted its holdings in Bruker by 8.3% in the first quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock worth $5,148,000 after acquiring an additional 9,501 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Bruker in the 1st quarter worth about $262,000. Goldman Sachs Group Inc. boosted its stake in Bruker by 107.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock worth $61,162,000 after purchasing an additional 758,301 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Bruker by 2.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock valued at $15,285,000 after purchasing an additional 9,235 shares during the last quarter. Finally, Focus Partners Wealth grew its position in Bruker by 115.0% during the 1st quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock valued at $469,000 after purchasing an additional 6,008 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker Trading Down 0.4%

Bruker stock opened at $57.70 on Friday. Bruker Corporation has a one year low of $28.53 and a one year high of $65.30. The business’s fifty day moving average is $58.36 and its 200 day moving average is $47.05. The stock has a market capitalization of $8.79 billion, a PE ratio of -82.43, a price-to-earnings-growth ratio of 1.77 and a beta of 1.28. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92.

Bruker (NASDAQ:BRKR) last issued its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. The business had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.Bruker’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, sell-side analysts predict that Bruker Corporation will post 2.12 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on BRKR shares. JPMorgan Chase & Co. raised their price objective on shares of Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a research note on Monday, June 8th. Zacks Research upgraded shares of Bruker from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 4th. Wall Street Zen raised shares of Bruker from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. UBS Group set a $60.00 price target on shares of Bruker in a research report on Wednesday, June 24th. Finally, Stifel Nicolaus set a $50.00 price objective on shares of Bruker in a report on Wednesday, August 5th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $56.64.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.